Downregulation of SELENBP1 Enhances Oral Squamous Cell Carcinoma Chemoresistance Through KEAP1-NRF2 Signaling

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2021 Apr 28

PMID 33907880

Citations 8

Authors

Hui Zeng

Xubing Zhao

Chengfang Tang

Affiliations

Soon will be listed here.

Abstract

Purpose: Limited value is achieved in systemic chemotherapy for oral squamous cell carcinoma (OSCC), due to cancer cell resistance against cytotoxic agents. Tumor suppressor activities of selenium-binding protein 1 (SELENBP1) have been shown in multiple human cancers except for OSCC. The aim of this study is to clarify the biological functions and potential mechanism of SELENBP1 in OSCC.

Methods: SELENBP1 expression and its clinical significance in OSCC were analyzed from The Cancer Genome Atlas (TCGA) database. Quantitative polymerase chain reaction (qPCR) or western blot was applied to determine SELENBP1, NRF2 and KEAP1 mRNA or protein levels. Sulforhodamine B assay (SRB) was performed to examine the cytotoxic effects of 5-fluorouracil (5-FU) and cisplatin on OSCC cells. Luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were conducted to investigate the role of SELENBP1 in KEAP1 transcription.

Results: SELENBP1 downregulation is positively correlated with a poor prognosis for OSCC patients. SELENBP1 knockdown enhances resistance of OSCC cells to 5-FU and cisplatin, while SENENBP1 overexpression displays the opposite effects. Mechanistically, SELENBP1 reduces NRF2 protein levels by promoting its polyubiquitination and degradation. SELENBP1 induces KEAP1 transcription by binding to KEAP1 promoter. Downregulation of SELENBP1 is induced by miR-4786-3p binding to the 3' untranslated region (UTR) of SELENBP1.

Conclusion: SENENBP1 is identified as a novel protective biomarker for OSCC patients. Targeting at the miR-4786-3p-SELENBP1-KEAP1-NRF2 signaling axis may enhance the efficacy of chemotherapy for OSCC.

Citing Articles

A novel hsa_circ_0006903 circular RNA promotes tumor development and dendritic cells activated expression in infantile hemangioma.

Gao X, Chen L, Zuo H, Li Q Heliyon. 2024; 10(14):e34186.

PMID: 39082028 PMC: 11284419. DOI: 10.1016/j.heliyon.2024.e34186.

PRDM1 promotes the ferroptosis and immune escape of thyroid cancer by regulating USP15-mediated SELENBP1 deubiquitination.

Ma J, Li Z, Xu J, Lai J, Zhao J, Ma L J Endocrinol Invest. 2024; 47(12):2981-2997.

PMID: 39014173 DOI: 10.1007/s40618-024-02385-4.

Targeting ferroptosis as a potential strategy to overcome the resistance of cisplatin in oral squamous cell carcinoma.

Chen R, Zhu S, Zhao R, Liu W, Jin L, Ren X Front Pharmacol. 2024; 15:1402514.

PMID: 38711989 PMC: 11071065. DOI: 10.3389/fphar.2024.1402514.

Methanethiol: A Scent Mark of Dysregulated Sulfur Metabolism in Cancer.

Philipp T, Scheller A, Krafczyk N, Klotz L, Steinbrenner H Antioxidants (Basel). 2023; 12(9).

PMID: 37760083 PMC: 10525899. DOI: 10.3390/antiox12091780.

MicroRNAs as the pivotal regulators of cisplatin resistance in head and neck cancers.

Tolue Ghasaban F, Maharati A, Zangouei A, Zangooie A, Moghbeli M Cancer Cell Int. 2023; 23(1):170.

PMID: 37587481 PMC: 10428558. DOI: 10.1186/s12935-023-03010-9.

References

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Huang S, OSullivan B . Oral cancer: Current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 2013; 18(2):e233-40. PMC: 3613874. DOI: 10.4317/medoral.18772. View

Wang C, Liu X, Hou J, Wang J, Huang H . Molecular Mechanisms of Chemoresistance in Oral Cancer. Chin J Dent Res. 2016; 19(1):25-33. DOI: 10.3290/j.cjdr.a35694. View

Chang P, Tsui S, Liew C, Lee C, Waye M, Fung K . Isolation, characterization, and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein. J Cell Biochem. 1997; 64(2):217-24. DOI: 10.1002/(sici)1097-4644(199702)64:2<217::aid-jcb5>3.0.co;2-#. View

Zhang S, Li F, Younes M, Liu H, Chen C, Yao Q . Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium. PLoS One. 2013; 8(5):e63702. PMC: 3660592. DOI: 10.1371/journal.pone.0063702. View

Zhang J, Dong W, Lin J . Reduced selenium-binding protein 1 is associated with poor survival rate in gastric carcinoma. Med Oncol. 2010; 28(2):481-7. DOI: 10.1007/s12032-010-9482-7. View

Xia Y, Ma Y, He X, Wang H, Ye Z, Tao H . Suppression of selenium-binding protein 1 in gastric cancer is associated with poor survival. Hum Pathol. 2011; 42(11):1620-8. DOI: 10.1016/j.humpath.2011.01.008. View

Huang C, Ding G, Gu C, Zhou J, Kuang M, Ji Y . Decreased selenium-binding protein 1 enhances glutathione peroxidase 1 activity and downregulates HIF-1α to promote hepatocellular carcinoma invasiveness. Clin Cancer Res. 2012; 18(11):3042-53. DOI: 10.1158/1078-0432.CCR-12-0183. View

Li T, Yang W, Li M, Byun D, Tong C, Nasser S . Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res. 2008; 52(11):1289-99. DOI: 10.1002/mnfr.200700331. View

10.

Chen G, Wang H, Miller C, Thomas D, Gharib T, Misek D . Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol. 2004; 202(3):321-9. DOI: 10.1002/path.1524. View

11.

Feng S, Wang S, Wang Y, Yang Q, Wang D, Li H . Identification and expression of carbonic anhydrase 2, myosin regulatory light chain 2 and selenium-binding protein 1 in zebrafish Danio rerio: Implication for age-related biomarkers. Gene Expr Patterns. 2018; 29:47-58. DOI: 10.1016/j.gep.2018.04.007. View

12.

Schott M, de Jel M, Engelmann J, Renner P, Geissler E, Bosserhoff A . Selenium-binding protein 1 is down-regulated in malignant melanoma. Oncotarget. 2018; 9(12):10445-10456. PMC: 5828193. DOI: 10.18632/oncotarget.23853. View

13.

Vichai V, Kirtikara K . Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2007; 1(3):1112-6. DOI: 10.1038/nprot.2006.179. View

14.

Chen D, Wang Y, Lu R, Jiang X, Chen X, Meng N . E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing. Theranostics. 2020; 10(19):8558-8572. PMC: 7392027. DOI: 10.7150/thno.44873. View

15.

Jiang T, Chen N, Zhao F, Wang X, Kong B, Zheng W . High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010; 70(13):5486-96. PMC: 2896449. DOI: 10.1158/0008-5472.CAN-10-0713. View

16.

Lian W, Liu X, Chen W . TNFα Induces Multidrug Resistance-Associated Protein 4 Expression through p38-E2F1-Nrf2 Signaling in Obstructive Cholestasis. Yonsei Med J. 2019; 60(11):1045-1053. PMC: 6813138. DOI: 10.3349/ymj.2019.60.11.1045. View

17.

Scott D, Rhee D, Duda D, Kelsall I, Olszewski J, Paulo J . Two Distinct Types of E3 Ligases Work in Unison to Regulate Substrate Ubiquitylation. Cell. 2016; 166(5):1198-1214.e24. PMC: 5091668. DOI: 10.1016/j.cell.2016.07.027. View

18.

Zhi X, Zhao D, Wang Z, Zhou Z, Wang C, Chen W . E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation. Cancer Res. 2012; 73(1):385-94. DOI: 10.1158/0008-5472.CAN-12-0562. View

19.

Adam J, Hatipoglu E, OFlaherty L, Ternette N, Sahgal N, Lockstone H . Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011; 20(4):524-37. PMC: 3202623. DOI: 10.1016/j.ccr.2011.09.006. View

20.

Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel J . Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999; 13(1):76-86. PMC: 316370. DOI: 10.1101/gad.13.1.76. View